Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2011-08-30
2011-08-30
Graser, Jennifer (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S234100, C424S236100, C424S240100, C424S238100, C424S239100, C424S245100, C424S201100, C424S193100, C536S123100
Reexamination Certificate
active
08007818
ABSTRACT:
The present invention relates to the field of vaccines, and in particular vaccines comprising antigens of low isoelectric point at pH 7.0, in particular the capsular polysaccharide or oligosaccharide ofH. influenzaeB (PRP). Immunogenic compositions and methods of making such compositions are presented in which the PRP is surprisingly protected from immune interference by adding a polyanionic polymer (such as PLG-poly-L-glutamic acid) to the composition.
REFERENCES:
patent: WO 98/17310 (1998-04-01), None
patent: WO 02/00249 (2002-01-01), None
Gupta et al., “Biodegradable Polymer Microspheres as Vaccine Adjuvants and Delivery Systems”.Developments in Biological Standardization, 92: 63-78 (1998).
Boehm-Gerard et al., “On Technological and Immunological Benefits of Multivalent Single-Injection Microsphere Vaccines”.Pharmaceutical Research, 19(9): 1330-1336 (2002).
Raghuvanshi et al., “Improved Immune Response from Biodegradable Polymer Particles Entrapping Tetanus Toxoid by use of Different Immunization Protocol and Adjuvants”.Int'l. J. Pharmaceutics, 245(1-2): 109-121 (2002).
Peyre et al., “An Experimental Divalent Vaccine Based on Biodegradable Microspheres induces Protective Immunity Against Tetanus and Diphtheria”.J. Pharm. Sci., 92(5): 857-966 (2003).
Gupta et al., “Evaluation of a Guinea Pig Model to Assess Interference in the Immunogenicity of Different Components of a Combination Vaccine Comprising Diphtheria, Tetanus and Acellular Pertussis (DTaP) Vaccine and Haemophilus Influenzae Type B Capsular Polysaccharide Conjugate Vaccine”.Biologicals, 27(2): 167-176 (1999).
Richard et al., “Production and Mass Transfer Characteristics of Non-Newtonian Biopolymers for Biomedical Applications”.CRC Critical Rev. in Biotechnol., 22(4): 355-374 (2002).
Nichol et al., “Poly-L-glutamage, an Anionic Polymer, Enhances Transgene Expression for Plasmids Delivered by Intramuscular Injection with in vivo Electroporation”.Gene Ther., 9(20): 1351-1358 (2000).
Milas et al., “Poly(L-glutamic acid)-Paclitaxel Conjugate is a Potent Enhancer of Tumor Radiocurability”.Int'l J. Radiation Oncol. Biol. Phys., 55(3): 707-712 (2003).
Yang et al., “Poly(glutamic acid) Poly(ethylene glycol) Hydrogels Prepared by Photoinduced Polymerization: Synthesis, Characterization, and Preliminary Release Studies of Protein Drugs”.J. Biomed. Materials Res., 62(1): 14-21 (2002).
Diwan et al., “Enhancement of Immune Responses by Co-Delivery of a CpG Oligodeoxynucleotide and Tetanus Toxoid in Biodegradable Nanospheres”.J. Controlled Rel., 85(1-3): 247-262 (2002).
Sanchez et al., “Formulation Strategies for the Stabilization of Tetanus Toxoid in Poly(lactide-co-glycolide) Microspheres”.Int'lJ. Pharmaceutics., 185(2): 255-266 (1999).
Esparza et al., “Parameters Affecting the Immunogenicity of Microencapsulated Tetanus Toxoid”.Vaccine, 10(10): 714-719 (1992).
GlaxoSmithKline NZ Ltd. “Datasheet—Hiberix”. New Zealand and Medical Devices Safety Authority, ′Online! 2002, XP002306401.
Jiang et al., “Stabilization of a Model Formalinized Protein Antigen Encapsulated in Poly(lactide-co-glycolide)-based Microspheres”.J. Pharm. Sci., 90(10): 1558-1569 (2001).
L.G. Payne, et al., PCPP as a parental adjuvant for diverse antigens, Dev Biol Stand, vol. 92, 79-87 (1998).
C. Von Hunolstein, et al.,The adjuvant effect of synthetic oligodeoxynucleotide containing CpG motif converts the anti-Haemophilus influenzae type b glycoconjugates into efficient anti-polysaccharide and anti-carrier polyvalent vaccines, Vaccine, vol. 19, 3058-3066 (2001).
D. L. Watson, et al.,Influence of adjuvants on the immune response of sheep to a novel Staphylococcus aureus vaccine, Veterinary Microbiology, vol. 34, 139-153 (1993).
Glaxosmithkline NZ Ltd,Datasheet—Hiberix, New Zealand Medicines And Medical Devices Safety Authority (2002).
Aldrich Handbook of Fine Chemicals and Laboratory Equipment, 2003-2004, United Kingdom, pp. 1529-1530.
Lactel® Absorbable Polymers MSDS for 50:50 poly(DL-lactide-co-glycolide), Apr. 8, 2008, from Birmingham Polymers, www.birminghampolymers.com, www.absorbables.com/documents/DL-PLGMSDS.pdf.
Garcon Nathalie Marie-Josephe
Lemoine Dominique
Wauters Florence Emilie Jeanne Francoise
Bradney Alice P.
GlaxoSmithKline Biologicals, S.R.
Graser Jennifer
LandOfFree
Polyanionic polymer adjuvants for haemophilus influenzae B... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Polyanionic polymer adjuvants for haemophilus influenzae B..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polyanionic polymer adjuvants for haemophilus influenzae B... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2745331